We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Bausch + Lomb (BLCO) This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Bausch + Lomb (BLCO - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Bausch + Lomb is a member of our Medical group, which includes 913 different companies and currently sits at #4 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Bausch + Lomb is currently sporting a Zacks Rank of #1 (Strong Buy).
The Zacks Consensus Estimate for BLCO's full-year earnings has moved 16.9% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
According to our latest data, BLCO has moved about 22.7% on a year-to-date basis. At the same time, Medical stocks have gained an average of 5.7%. This means that Bausch + Lomb is outperforming the sector as a whole this year.
Chemed (CHE - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 27.8%.
For Chemed, the consensus EPS estimate for the current year has increased 1.5% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Bausch + Lomb belongs to the Medical Services industry, which includes 70 individual stocks and currently sits at #49 in the Zacks Industry Rank. On average, stocks in this group have gained 4.5% this year, meaning that BLCO is performing better in terms of year-to-date returns.
In contrast, Chemed falls under the Medical - Outpatient and Home Healthcare industry. Currently, this industry has 14 stocks and is ranked #97. Since the beginning of the year, the industry has moved +28.9%.
Bausch + Lomb and Chemed could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
Image: Bigstock
Are Medical Stocks Lagging Bausch + Lomb (BLCO) This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Bausch + Lomb (BLCO - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Bausch + Lomb is a member of our Medical group, which includes 913 different companies and currently sits at #4 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Bausch + Lomb is currently sporting a Zacks Rank of #1 (Strong Buy).
The Zacks Consensus Estimate for BLCO's full-year earnings has moved 16.9% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
According to our latest data, BLCO has moved about 22.7% on a year-to-date basis. At the same time, Medical stocks have gained an average of 5.7%. This means that Bausch + Lomb is outperforming the sector as a whole this year.
Chemed (CHE - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 27.8%.
For Chemed, the consensus EPS estimate for the current year has increased 1.5% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Bausch + Lomb belongs to the Medical Services industry, which includes 70 individual stocks and currently sits at #49 in the Zacks Industry Rank. On average, stocks in this group have gained 4.5% this year, meaning that BLCO is performing better in terms of year-to-date returns.
In contrast, Chemed falls under the Medical - Outpatient and Home Healthcare industry. Currently, this industry has 14 stocks and is ranked #97. Since the beginning of the year, the industry has moved +28.9%.
Bausch + Lomb and Chemed could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.